Top News
Home >> Tag Archives: Beckman Coulter Diagnostics—

Tag Archives: Beckman Coulter Diagnostics—

Beckman Coulter adds 6-AM and BUP assays, 4/18

April 2018—Beckman Coulter Diagnostics announced the addition of 6-acetylmorphine and buprenorphine assays to its menu of drugs-of-abuse tests for use on its AU chemistry analyzers (AU480, AU680, AU5800). The Syva Emit II Plus 6-AM assay provides a convenient and quick way to selectively screen for heroin use, in place of methods such as gas chromatography and mass spectrometry.

Read More »

Beckman introduces Access Sensitive Estradiol

April 11, 2018—Beckman Coulter Diagnostics announced the launch of its Access Sensitive Estradiol assay in the U.S. and in a majority of markets worldwide. The test is commonly ordered for detecting estradiol levels in women, children, and men. The assay aims to help laboratories deliver more accurate results for patients seeking answers to reproductive health questions. It has a broad ...

Read More »

FDA-cleared Access AMH immunoassay, 3/18

March 2018—Beckman Coulter Diagnostics announced FDA clearance of its automated Access AMH immunoassay for in vitro diagnostic use. This test aids health care providers in the assessment of a woman’s ovarian reserve and helps guide the clinical management of women struggling with infertility or planning to become pregnant later in life.

Read More »

Access AMH immunoassay gets FDA OK

Dec. 29, 2017—Beckman Coulter Diagnostics announced FDA clearance for its automated Access AMH immunoassay for in vitro diagnostic use. This test aids health care providers in the assessment of a woman’s ovarian reserve and helps guide the clinical management of women struggling with infertility or planning to become pregnant later in life. The Access AMH assay is a paramagnetic particle chemiluminescent ...

Read More »

Study: fewer biopsies for men tested with phi

Nov. 29, 2017—A study published in Prostate Cancer and Prostatic Diseases (White J, et al. Epub ahead of print Nov. 20, 2017. doi:10.1038/s41391-017-0008-7) demonstrated that physicians elected to perform fewer biopsies when Prostate Health Index (phi) testing was included in their overall, routine, clinical assessment. Phi testing is recommended for men presenting with elevated serum total prostate-specific antigen in the 4–10 ...

Read More »
X